Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations
Satoshi Oizumi(Hokkaido University), Toshihiro Nukiwa(Tohoku University), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Kunihiko Kobayashi(Saitama International Medical Center), Koichi Minato, Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Shinichi Fukumoto, Yoshiki Demura(Ishikawa Prefectural Central Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Satoshi Morita(Kyoto University), Yuka Fujita, Kazuhiko Ito(Niigata City General Hospital), Keisuke Aiba, Toshiyuki Harada(Hokkaido hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 43
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953